enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium

enVVeno Medical (NVNO) will present its investigational enVVe System at the annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Diego.

Rhea-AI Summary

enVVeno Medical (NVNO) will present its investigational enVVe System at the annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Diego. Chief Executive Officer Rob Berman is scheduled to deliver the presentation during the Innovation in Endovascular Therapies session on November 2, 2026, at 11:30 a.m. PT. The presentation, titled “Changing the Treatment Paradigm for Deep Venous Disease: Transcatheter Replacement Venous Valve,” will introduce cardiovascular specialists to the system, which is designed to restore one-way blood flow in deep veins.

Key Terms

transcatheter, deep venous insufficiency, chronic venous insufficiency, bioprosthetic

4 terms

transcatheter technical

"potential of a transcatheter approach to treating severe deep venous insufficiency"

Transcatheter describes medical procedures or devices delivered through a thin, flexible tube (catheter) that is threaded through blood vessels or small body openings to reach the heart or other organs without open surgery. It matters to investors because transcatheter approaches enable faster recovery, shorter hospital stays and larger patient pools for treatments that once required major operations, which can expand market demand and affect device and hospital revenues.

deep venous insufficiency medical

"transcatheter approach to treating severe deep venous insufficiency"

Deep venous insufficiency is a condition where the one-way valves in the deep veins of the legs fail, letting blood pool or flow backward instead of returning efficiently to the heart — imagine valves in a pipe that no longer close properly. For investors, it matters because it drives demand for treatments, diagnostic tests and medical devices, influences healthcare spending and reimbursement trends, and can affect the commercial prospects and regulatory risk for companies developing related therapies.

chronic venous insufficiency medical

"patients with chronic venous insufficiency"

A long-term condition in which the one-way valves in leg veins do not work properly, causing blood to pool, swelling, pain, skin changes or ulcers; think of it as a plumbing problem where backflow wears out pipes and fixtures. Investors care because it is a common, chronic market with ongoing demand for treatments, devices and wound-care products, and outcomes depend on clinical data, regulatory approvals and reimbursement decisions that affect revenue streams.

bioprosthetic medical

"advancement of innovative bioprosthetic (tissue-based) solutions"

A bioprosthetic is a medical implant made from biological tissues—often animal or human-derived—used to replace or support body parts like heart valves or joints. Think of it as a natural-material replacement part that mimics living tissue; it matters to investors because its performance, durability, manufacturing complexity, and regulatory approval drive clinical adoption, repeat procedures, reimbursement and long-term revenue potential for companies that develop or sell these devices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, CA / ACCESS Newswire / November 2, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it will present its investigational enVVe System® at the 38^th annual Transcatheter Cardiovascular Conference (TCT^®) in San Diego, CA.

The presentation, titled "Changing the Treatment Paradigm for Deep Venous Disease: Transcatheter Replacement Venous Valve," will be delivered by Rob Berman, Chief Executive Officer of enVVeno Medical, during the Innovation in Endovascular Therapies session on Monday, November 2, 2026 at 11:30 a.m. PT.

TCT is the world's premier scientific symposium dedicated to interventional cardiovascular medicine, bringing together more than 10,000 physicians, researchers, investors and healthcare leaders from around the globe. The presentation will introduce the enVVe System to a global audience of cardiovascular specialists and highlight the potential of a transcatheter approach to treating severe deep venous insufficiency.

"We are excited to have this opportunity to bring the enVVe System to one of the most prominent global forums in cardiovascular medicine," said Rob Berman, Chief Executive Officer of enVVeno Medical. "Deep venous insufficiency represents a significant unmet medical need, and we believe that enVVe has the potential to establish a new treatment paradigm for DVI. We look forward to introducing enVVe to the global cardiovascular community as will continue to provide updates we advance the enVVe System through its pivotal clinical study."

About the enVVe System

The investigational enVVe System is a transcatheter-delivered replacement venous valve designed to restore one-way blood flow in the deep veins of patients with chronic venous insufficiency. An estimated 3 million people in the U.S. suffer from severe deep venous insufficiency and it remains one of the largest unmet needs in vascular medicine. As venous valves fail, patients often experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life.

Despite the significant burden of DVI, treatment options remain limited and are primarily focused on managing symptoms through compression therapy and wound care rather than addressing the underlying cause: dysfunctional venous valves. The enVVe System is being developed to address this critical treatment gap by helping restore proper directional blood flow to the deep venous system.

About TCT

Presented annually by the Cardiovascular Research Foundation (CRF®), TCT is a global leader in interventional cardiovascular medicine, driving innovation, pioneering groundbreaking research, and transforming education. The conference showcases advances in clinical research, emerging technologies and innovative treatment approaches while providing education to healthcare professionals worldwide.

For more information about the TCT Symposium, please visit the conference website here.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire